Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:

Dupilumab: An emerging therapy in allergic fungal rhinosinusitisKey Points:

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis...

Full description

Bibliographic Details
Main Authors: Adeeb A. Bulkhi, MD, MSc, Ahmad A. Mirza, MBBS, MSc, Abdullah J. Aburiziza, MD, ABP, Osama A. Marglani, MD, FRCSC
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:World Allergy Organization Journal
Subjects:
Biological therapies
Hypersensitivity
Nasal polyp
Sinusitis
Saudi Arabia
Online Access:http://www.sciencedirect.com/science/article/pii/S193945512200014X

Internet

http://www.sciencedirect.com/science/article/pii/S193945512200014X

Similar Items